<DOC>
	<DOCNO>NCT00038558</DOCNO>
	<brief_summary>Prophylactic use Filgrastim SD/01 patient Hodgkin 's lymphoma receiving ABVD chemotherapy .</brief_summary>
	<brief_title>Prophylactic Use Filgrastim SD/01 Patients With Hodgkin 's Disease Receiving ABVD Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION : Previously untreated Hodgkin 's disease patient schedule receive standard ABVD chemo . Histologically proven diagnosis Hodgkin 's disease type . Bidimensionally measurable disease . Signed informed consent . Age &gt; /= 16 yr . Adequate bone marrow reserve ( ANC &gt; 1000/uL , Platelet &gt; 100,000/uL . LVEF &gt; /=50 % MUGA scan echocardiogram . Serum creatinine &lt; 2mg/dL ; serum bilirubin &lt; 2mg/dL . EXCLUSION : HIV positive . Pregnant woman child bear age use adequate contraception . Prior chemotherapy . Severe pulmonary disease include COPD asthma . History prior sensitivity E.coli derive product .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>DTIC</keyword>
	<keyword>DTIC-Dome</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>Velban</keyword>
	<keyword>Bleomycin sulfate</keyword>
	<keyword>Blenoxane</keyword>
	<keyword>BLM</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>granulocyte colony-stimulating factor</keyword>
</DOC>